New Data Underscore the Utility of CAPHOSOL in Treating Oral Mucositis
PRINCETON, N.J., May 21 /PRNewswire/ -- New data show that CAPHOSOL(R) (http://www.caphosol.com), an advanced electrolyte solution, relieves painful oral mucositis (OM) and improves quality of life for cancer patients undergoing chemotherapy and radiation therapy. These data were reported in two separate presentations last week at the 33rd Annual Congress of the Oncology Nursing Society (ONS) in Philadelphia. These data confirm that CAPHOSOL is a useful tool to help oncology nurses and other healthcare professionals in the management of OM and related symptoms, particularly in patients with head and neck cancer and those receiving chemotherapy.
One of the two abstracts including this data, ONS Abstract #2757, "Supersaturated Electrolyte Oral Rinse Aids Quality of Life for Head/Neck Chemoradiation Patients" (Haas, ML), was selected by an ONS Expert Panel as one of the Top Ten Best Supportive Care abstracts at the ONS 2008 Congress.
"Oral mucositis is a painful, common side effect experienced by cancer patients receiving chemotherapy and radiation therapy," commented principal investigator Marilyn L. Haas, PhD, RN, CNS, ANP-C, Nurse Practitioner, Mountain Radiation Oncology, Asheville, N.C. "As layers of epithelial cells in the oral cavity (cells lining the surface of the throat and esophagus) are eroded during therapy, patients often experience severe pain, are more prone to infection and have difficulty eating and swallowing. Our research concludes that CAPHOSOL, a supersaturated electrolyte oral rinse, should be introduced early in the course of cancer therapy for patients at high risk of oral mucositis because it minimizes the onset and severity of symptoms."
The rate of severe oral mucositis (NCI Clinical OM Grade 3-4) reported by head and neck cancer patients using CAPHOSOL in this study was 11% (Grade 3) and 2% (Grade 4). Historically, the incidence of severe OM in head and neck cancer patients receiving radiation typically ranges from 34% - 56%, depending upon the specific type of treatment.
Relief of Painful Oral Mucositis
Oncologists at 26 sites enrolled 217 patients into this open-label, non-randomized observational study, called the CAPHOSOL Oral Mucositis Follow-up Observational Registry Trial (COMFORT). Patients must have been undergoing chemotherapy and radiation and at high risk of developing OM. Thirty-one percent of the patients had head and neck cancer (HNC), 31 percent had breast cancer, 13 percent had colon cancer, eight percent had lung cancer, six percent had lymphoma and 11 percent had other tumor types. All patients in this study received CAPHOSOL, administered as an oral rinse, four to 10 times daily for an average of six to eight weeks beginning the first day of treatment. Data were reported for 171 of these patients who had completed follow-up at the time the data were analyzed for this interim report.
The study showed that 95 percent of the patients reported favorable OM scores as measured by the percentages of patients indicating Grade 0 (no adverse effects or within normal limits), Grade 1 (mild) or Grade 2 (moderate) symptom severity.
The National Cancer Institute (NCI) clinical rating for OM (oral mucositis assessed during a clinical evaluation) of Grade 0 was evident in 61 percent of patients and Grade 1 clinical OM was seen in 20 percent. An NCI functional rating of OM (reflective of how OM affects diet, swallowing, gastrointestinal function and quality of life) of Grades 0 and 1 were reported in 81 percent of patients. Sixty-five percent of patients ranked their dysphagia symptoms (difficulty swallowing) as Grade 0, while 15 percent rated their symptoms as Grade 1. Grade 0 pain was reported by 61 percent of patients and 20 percent assessed their pain as Grade 1.
Out of 112 patients undergoing chemotherapy alone, 78 percent indicated a clinical OM rating of Grade 0 and 79 percent indicated a functional OM rating of Grade 0. Moreover, 23 percent of the 56 patients undergoing radiation therapy alone or in combination with chemotherapy (RT +/- chemo) indicated a clinical OM rating of Grade 0, and 34 percent indicated a functional OM rating of Grade 0. With regard to pain 79 percent of patients undergoing chemotherapy alone and 25 percent of RT +/- chemo-treated patients rated their pain as Grade 0. For dysphagia, eighty-two percent of chemotherapy-treated patients and 30 percent of those undergoing RT +/- chemo treatment reported a dysphagia Grade of 0.
These data confirm that early intervention with CAPHOSOL reduces the occurrence and severity of OM, dysphagia and oral pain in patients undergoing chemotherapy, radiation or combination therapy treatments for cancer.
Quality-of-Life Benefits in Patients with Head/Neck Cancer
Oral mucositis occurs in nearly all chemoradiation patients with HNC. A subset analysis of data from 67 HNC patients from the study were presented in a poster entitled, "Supersaturated Electrolyte Oral Rinse Aids Quality of Life for Head/Neck Chemoradiation Patients." These data confirm high levels of patient and practitioner satisfaction with CAPHOSOL, suggestive of quality-of- life benefits. The poster reports that more than half (52 percent) of the HNC patients said they were "very satisfied" with CAPHOSOL in terms of pain relief and oral comfort. None of the HNC patients reported being unsatisfied with CAPHOSOL.
This study showed that among practitioners treating HNC patients, 16 percent of practitioners reported no signs of OM in their patients at the end of the study, and 70 percent assigned an "excellent or good" rating to CAPHOSOL because none of their patients required additional therapies. Ninety-six percent of the patients indicated they would recommend CAPHOSOL to other patients at high risk of OM.
"Considering that most patients with head and neck cancer experience oral mucositis, any improvements in quality of life for these patients is encouraging," said Dr. Haas. "CAPHOSOL is useful for oncology nurses and other healthcare practitioners in helping patients with oral pain and related symptoms of chemoradiation-induced oral mucositis."
Oral Mucositis: A Common and Debilitating Condition
Oral complications including mucositis and salivary gland dysfunction are common and often debilitating side effects of cancer therapy. OM is estimated to affect more than 400,000 cancer patients each year. OM affects approximately 40 percent of cancer patients who receive chemotherapy, more than 70 percent of those undergoing conditioning therapy for bone marrow transplantation, and virtually all patients receiving radiation therapy for head and neck cancer.
Oral mucositis usually manifests itself within seven to 14 days after initiation of therapy. Initial signs and symptoms include redness, swelling and ulceration of the mucosa. Oral mucositis can cause mouth pain, xerostomia (dryness of the mouth or throat), difficulty eating and drinking, as well as difficulty with speech; these effects can significantly impact a patient's weight, mood and physical functioning. Severe ulceration may cause breaks in the mucosa, which can then become susceptible to oral opportunistic infections, possibly resulting in bacteremia (the presence of bacteria in the blood), sepsis (the presence of pathogenic microorganisms in the blood) or other potentially fatal complications. The economic impact of mucositis can be significant, as the need for prolonged hospital stays, nutritional therapy and treatments for pain and infection can drive up the costs of therapy.
CAPHOSOL is an advanced electrolyte solution indicated in the U.S. as an adjunct to standard oral care in treating OM caused by radiation or high dose chemotherapy. CAPHOSOL, a U.S. patented prescription medical device, is also indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause or whether the conditions are temporary or permanent. Patients restricted to a low sodium diet should consult their physician before use. Patients should avoid eating or drinking at least 15 minutes after use.
As part of its commitment to advancing the treatment and care of cancer patients, Cytogen launched CARE OM(TM) (http://www.careom.com) a Web-based education and support center for patients and caregivers seeking to learn more about OM and CAPHOSOL. In addition to oral mucositis educational material and support information, visitors to CARE OM can also download an OM brochure or request it by mail. For more information about CAPHOSOL, visit http://www.caphosol.com or call (800) 833-3533.
About EUSA Pharma Inc.
EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has nine products on the global market, including CAPHOSOL(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint(R) for imaging the extent and spread of prostate cancer, Quadramet(R) for the treatment of pain in patients whose cancer has spread to the bones, Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, the antibiotic surgical implant Collatamp(R) G, and Rapydan(R), a rapid-onset anesthetic patch which recently received Europe-wide approval. EUSA also has several products in late-stage development, notably Collatamp(R) G topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx(R) bupivacaine implant* for local post-surgical pain control.
Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.
For more information please visit http://www.eusapharma.com .
|SOURCE EUSA Pharma Inc.|
Copyright©2008 PR Newswire.
All rights reserved